Immunoglobulin E and Matrix Metalloproteinase-9 in Patients with Different Stages of Coronary Artery Diseases

Gwo-Ping Jong；Yuh-Feng Wang；Fuu-Jen Tsai；Chang-Hai Tsai；Ching-Lin Wu；Rosa Huang Liu；Dennis Jine-Yuan Hsieh；Fu-Yang Ko；Chih-Yang Huang；Shin-Da Lee

IgE ； MMP ； ischemic heart disease ； coronary artery bypass grafts

The Chinese Journal of Physiology

50卷6期（2007 / 12 / 01）

277 - 282

英文

The aims of this study were to identify levels of total immunoglobulin E (IgE) and matrix metalloproteinase (MMP)-9 in patients with different stages of coronary artery diseases. IgE, MMP-9, creatine phosphokinase (CPK), lactate dehydrogenase (LDH), total cholesterol, low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL) and triglyceride (TG) were measured by fluorescence enzyme immunoassay, gelatin zymography, and autoanalyzer in normal subjects (n=40), patients with stable angina pectoris (SAP, n=40), patients with unstable angina pectoris (UAP, n=40), patients with acute myocardial infarction (AMI, n=40), or post-CABG-surgery of those acute myocardial infarction (PCABG, n=40). Compared with normal subjects, increased IgE but unchanged MMP-9, CPK, LDH were found in SAP group and UAP group, whereas IgE, MMP-9, CPK and LDH levels were all significantly increased in AMI group. IgE, MMP-9, CPK and LDH levels in P-CABG group were significantly reduced, compared with AMI group, and were similar to those in normal subjects. Cholesterol, LDL, HDL and TG were not significantly changed in all groups. We suggest that serum total IgE can be an early marker of coronary artery disease and MMP-9 is a marker of acute myocardial infarction.

1. Jong, G.P.,Ma, T.,Chou, P.,Chang, M.H.,Wu, C.H.,Lis, P.C.,Lee, S.D.,Liu, J.Y.,Kuo, W.W.,Huang, C.Y.(2006).Serum MMP-9 activity as a diagnosing marker for the developing heart failure of post MI patients.Chinese J. Physiol.,49,104-109.
   連結：
2. Akyol, O.,Sencan, O.,Buyukberber, S.,Canbolat, O.,Durak, I.(1993).Glutathione peroxidase activity in serum during acute myocardial infarction and unstable angina pectoris..Jpn. Heart J.,34,551-555.
3. Benjamin, I.J.(2001).Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease.J. Investig. Med.,49,381-397.
4. Blatterlein, I.,Lehmann, I.,Wagenknecht, C.(1977).Pre-, intra- and postoperative behavior of LDH and GOT isoenzymes in the plasma of patients with chronic ischemic heart disease.Z. Gesamte Inn. Med.,32,307-309.
5. Erdogan, O.,Gul, C.,Altun, A.,Ozbay, G.(2003).Increased immunoglobulin E response in acute coronary syndromes.Angiology,54,73-79.
6. Ezaki, H.,Matsushita, S.,Ohkawa, S.,Kuramoto, K.(1987).Comparison of enzymatic, anatomic and electrocardiographic estimates of myocardial infarct size in man.Jpn. Circ. J.,51,374-382.
7. Friedewald, W.T.,Levy, R.I.,Fredrickson, D.S.(1972).Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clin. Chem.,18,499-502.
8. Ginsburg, R.,Bristow, M.R.,Kantrowitz, N.,Baim, D.S.,Harrison, D.C.(1981).Histamine provocation of clinical coronary artery spasm: implications concerning pathogenesis of variant angina pectoris.Am. Heart J.,102,819-822.
9. Horie, M.,Yasue, H.,Omote, S.,Takizawa, A.,Nagao, M.,Nishida, S.,Kubota, J.(1984).The effects of reperfusion of infarct-related coronary artery on serum creatine phosphokinase and left ventricular function..Jpn. Circ. J.,48,539-545.
10. Janicki, J.S.,Brower, G.L.,Gardner, J.D.,Chancey, A.L.,Stewart, J.A.(2004).The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling.Heart Fail. Rev,9,33-42.
11. Kai, H.,Ikeda, H.,Yasukawa, H.,Kai, M.,Seki, Y.,Kuwahara, F.,Ueno, T.,Sugi, K.,Imaizumi, T.(1998).Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes..J. Am. Coll. Cardiol.,32,368-372.
12. Korkmaz, M.E.,Oto, A.,Saraclar, Y.,Oram, E.,Oram, A.,Ugurlu, S.,Karamehmetoglu, A.,Karaagaoglu, E.(1991).Levels of IgE in the serum of patients with coronary arterial disease.Int. J. Cardiol.,31,199-204.
13. Langer, R.D.,Criqui, M.H.,Feigelson, H.S.,McCann, T.J.,Hamburger, R.N.(1996).IgE predicts future nonfatal myocardial infarction in men.J. Clin. Epidemiol,49,203-209.
14. Lee, S.D.,Chen, L.M.,Kuo, W.W.,Shu, W.T.,Kuo, W.H.,Huang, E.J., Tsai, C.C.,Li, P.C.,Liu, J.Y.,Chen, T.H.,Huang, C.Y.(2006).Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease.Clin. Chim. Acta,367,62-68.
15. Mair, J.(1997).Progress in myocardial damage detection: new biochemical markers for clinicians.Crit. Rev. Clin. Lab. Sci.,34,1-66.
16. Phillips, J.E.(1974).CPK and LDH isoenzymes in the diagnosis of myocardial infarctions.J. Med. Assoc. Ga.,63,382-383.
17. Plebani, M.(2001).Biochemical markers of cardiac damage: from efficiency to effectiveness.Clin. Chim. Acta,311,3-7.
18. Ruzich, R.S.(1992).Cardiac enzymes. How to use serial determinations to confirm acute myocardial infarction.Postgrad. Med.,92,85-92.
19. Sobel, B.E.,LeWinter, M.M.(2000).Ingenuous interpretation of elevated blood levels of macromolecular markers of myocardial injury: a recipe for confusion..J. Am. Coll. Cardiol.,35,1355-1358.
20. Szczeklik, A.,Dropinski, J.,Gora, P.F.(1993).Serum immunoglobulin E and sudden cardiac arrest during myocardial infarction.Coron. Artery Dis.,4,1029-1032.
21. Szczeklik, A.,Sladek, K.,Szczerba, A.,Dropinski, J.(1988).Serum immunoglobulin E response to myocardial infarction..Circulation,77,1245-1249.
22. Tsicopoulos, A.,Tonnel, A.B.,Wallaert, B.,Joseph, M.,Ramon, P.,Capron, A.(1989).A circulating suppressive factor of platelet cytotoxic functions after rush immunotherapy in Hymenoptera venom hypersensitivity..J. Immunol.,142,2683-2688.
23. Tziakas, D.N.,Chalikias, G.K.,Parissis, J.T.,Hatzinikolaou, E.I.,Papadopoulos, E.D.,Tripsiannis, G.A.,Papadopoulou, E.G.,Tentes, I.K.,Karas, S.M.,Chatseras, D.I.(2004).Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration..Int. J. Cardiol.,94,269-277.
24. Walter, S.,Carlsson, J.,Schroder, R.,Neuhaus, K.L.,Sorges, E.,Tebbe, U.(1999).Enzymatic markers of reperfusion in acute myocardial infarct. With data from the ISAM study.Herz,24,430-439.